Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection.

A recent publication in The Lancet Respiratory Medicine reports the results of the international phase 3 PROMIS-I and PROMIS-II studies investigating inhaled colistimethate sodium in people with bronchiectasis and chronic Pseudomonas aeruginosa infection.

The studies examined whether regular inhaled antibiotic treatment can reduce exacerbations and improve disease control. In PROMIS-I, colistimethate sodium significantly reduced the annual exacerbation rate compared with placebo. The second study, PROMIS-II, did not clearly confirm this effect; however, it was terminated early during the COVID-19 pandemic.

Overall, the treatment was well tolerated, with adverse events occurring at a similar frequency to those observed in the placebo group. The findings provide important new evidence on the potential benefit of inhaled antibiotics in bronchiectasis, while also highlighting the need for further research into optimal patient selection and treatment use.

This publication represents a relevant contribution to the further development of care for patients with bronchiectasis and chronic bacterial infection.

Read the full article